Approaches for targeting cancer stem cells drug resistance

Expert Opinion on Drug Discovery

Volumn 11, Issue 12, 2016, Pages 1201-1212

  Rosa, Roberta ^a   D’Amato, Valentina ^a   De Placido, Sabino ^a   Bianco, Roberto ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer stem cells; EMT; immune evasion; resistance; stemness

Indexed keywords

CANCER RESISTANCE; CANCER STEM CELL; DNA REPAIR; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; ANIMAL; DRUG RESISTANCE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; RESEARCH DESIGN;

EID: 84994589210     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1243525     Document Type: Review

References (119)

1. T.Reya, S.J.Morrison, M.F.Clarke, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. doi:10.1038/35102167
2. L.Ghisolfi, A.C.Keates, X.Hu, et al. Ionizing radiation induces stemness in cancer cells. PLoS One. 2012;7:e43628. doi:10.1371/journal.pone.0043628
3. F.Marcucci, C.Rumio, F.Lefoulon Anti-cancer stem-like cell compounds in clinical development – an overview and critical appraisal. Front Oncol. 2016;6:115. doi:10.3389/fonc.2016.00115•• A review on clinical development of anticancer stem cell compounds.
4. L.Ricci-Vitiani, D.G.Lombardi, E.Pilozzi, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115. doi:10.1038/nature05384
5. L.Vermeulen, F.de Sousa e Melo, D.J.Richel, et al. The developing cancer stem-cell model:clinical challenges and opportunities. Lancet Oncol. 2012;13:e83–e89. doi:10.1016/S1470-2045(11)70257-1
6. J.E.Visvader. Cells of origin in cancer. Nature. 2011;469:314–322. doi:10.1038/nature09781
7. F.Marcucci, M.Bellone, C.A.Caserta, et al. Pushing tumor cells towards a malignant phenotype:stimuli from the microenvironment, intercellular communications and alternative roads. Int J Cancer. 2014;135:1265–1276. doi:10.1002/ijc.v135.6
8. A.P.Vaz, S.Deb, S.Rachagani, et al. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:3317–3331. doi:10.18632/oncotarget.6580
9. Y.Wang, H.Cardenas, F.Fang, et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014;74:4922–4936. doi:10.1158/0008-5472.CAN-14-1022
10. J.M.Catanzaro, N.Sheshadri, J.A.Pan, et al. Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun. 2014;5:3729. doi:10.1038/ncomms5972
11. S.A.Mani, W.Guo, M.J.Liao, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715. doi:10.1016/j.cell.2008.03.027
12. K.Polyak, R.A.Weinberg. Transitions between epithelial and mesenchymal states:acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–273. doi:10.1038/nrc2620
13. D.R.Pattabiraman, R.A.Weinberg. Tackling the cancer stem cells – what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512. doi:10.1038/nrd4253
14. M.Shackleton. Normal stem cells and cancer stem cells:similar and different. Semin Cancer Biol. 2010;20:85–92. doi:10.1016/j.semcancer.2010.04.002
15. A.Mitra, L.Mishra, S.Li. EMT, CTCs, CSCs in tumor relapse and drug-resistance. Oncotarget. 2015;6:10697–10711. doi:10.18632/oncotarget
16. S.Zhou, J.D.Schuetz, K.D.Bunting, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028–1034. doi:10.1038/nm0901-1028
17. G.Liu, X.Yuan, Z.Zeng, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.
18. R.C.Bates, N.S.Edwards, G.F.Burns, et al. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001;61:5275–5283.
19. S.Sarvi, A.C.Mackinnon, N.Avlonitis, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74:1554–1565. doi:10.1158/0008-5472.CAN-13-1541
20. J.Fernando, A.Malfettone, E.B.Cepeda, et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer. 2015;136:E161–E172. doi:10.1002/ijc.29097
21. N.Hashimoto, R.Tsunedomi, K.Yoshimura, et al. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer. 2014;14:722. doi:10.1186/1471-2407-14-722
22. Y.Li, J.Ma, X.Qian, et al. Regulation of EMT by Notch signaling pathway in tumor progression. Curr Cancer Drug Targets. 2013;13:957–962. doi:10.2174/15680096113136660101
23. M.Saxena, M.Stephens, H.Pathak, et al. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179. doi:10.1038/cddis.2011.82
24. W.H.Liu, M.T.Chen, M.L.Wang, et al. Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells. Oncotarget. 2015;6:1750–1768. doi:10.18632/oncotarget.2737
25. Y.Kong, Y.Peng, Y.Liu, et al. Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters. Stem Cells. 2015;33:1063–1074. doi:10.1002/stem.1955
26. Z.Wang, Y.Li, D.Kong, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;15(69):2400–2407. doi:10.1158/0008-5472.CAN-08-4312
27. X.Zheng, J.L.Carstens, J.Kim, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–530. doi:10.1038/nature15724
28. L.Chang, P.H.Graham, J.Hao, et al. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013;4:e875. doi:10.1038/cddis.2013.407• It demonstrates that BEZ235 reduces expression of EMT/CSC markers in prostate cancers.
29. M.Garg. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells:therapeutic approaches in cancer. Expert Opin Ther Targets. 2015;19:285–297. doi:10.1517/14728222.2014.975794
30. Y.Zhang, L.Zheng, J.Huang, et al. MiR-124 radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS One. 2014;9:e93917. doi:10.1371/journal.pone.0093917
31. J.Ma, B.Fang, F.Zeng, et al. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget. 2015;6:1740–1749. doi:10.18632/oncotarget.2714
32. W.Bai, X.Ye, M.Zhang, et al. MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer. 2014;135:1356–1368. doi:10.1002/ijc.28782
33. S.Meidhof, S.Brabletz, W.Lehmann, et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med. 2015;7:831–847. doi:10.15252/emmm.201404967
34. C.Padua Alves, A.S.Fonseca, B.R.Muys, et al. Brief report:the lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells. 2013;31:2827–2832. doi:10.1002/stem.1547
35. L.Wu, P.Murat, D.Matak-Vinkovic, et al. Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins. Biochemistry. 2013;52:9519–9527. doi:10.1021/bi401085h
36. C.Peitzsch, M.Cojoc, L.Hein, et al. An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells. Cancer Res. 2016;76:2637–2651. doi:10.1158/0008-5472.CAN-15-2116
37. J.Codony-Servat, R.Rosell. Cancer stem cells and immunoresistance:clinical implications and solutions. Transl Lung Cancer Res. 2015;4:689–703. doi:10.3978/j.issn.2218-6751.2015.12.11•• A review on the mechanisms of immune evasion by CSCs.
38. S.Bandhavkar. Cancer stem cells:a metastasizing menace!. Cancer Med. 2016;5:649–655. doi:10.1002/cam4.629
39. V.G.Brunton, M.C.Frame. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol. 2008;8:427–432. doi:10.1016/j.coph.2008.06.012
40. S.Mustjoki, J.Richter, G.Barbany, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 2013;27:1520–1526. doi:10.1038/leu.2013.19
41. Clinical Trials.Gov. ID NCT02372227. Available from: www.clinicaltrials.org
42. S.F.Jones, L.L.Siu, J.C.Bendell, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33:1100–1107. doi:10.1007/s10637-015-0282-y
43. I.M.Shapiro, V.N.Kolev, C.M.Vidal, et al. Merlin deficiency predicts FAK inhibitor sensitivity:a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68. doi:10.1126/scitranslmed.3008639• It shows that FAK inhibitor VS-4718 could induce a durable antitumor response through reduction of CSCs.
44. B.Y.Lee, F.Hochgräfe, H.M.Lin, et al. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther. 2014;13:190–201. doi:10.1158/1535-7163.MCT-13-0225-T
45. L.M.Thorpe, H.Yuzugullu, J.J.Zhao. PI3K in cancer:divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7–24. doi:10.1038/nrc3860
46. V.N.Kolev, Q.G.Wright, C.M.Vidal, et al. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 2015;75:446–455. doi:10.1158/0008-5472.CAN-14-3569• It reports that VS-5584 preferentially reduces CSCs in surgically resected breast and ovarian patient tumors.
47. J.Chen, R.Shao, F.Li, et al. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clin Exp Pharmacol Physiol. 2015;42:1317–1326. doi:10.1111/1440-1681.12493
48. A.A.Samatar, P.I.Pulikakos. Targeting RAS-ERK signalling in cancer:promises and challenges. Nat Rev Drug Discov. 2014;13:928–942. doi:10.1038/nrd4281
49. J.M.Balko, L.J.Schwarz, N.E.Bhola, et al. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013;73:6346–6358. doi:10.1158/0008-5472.CAN-13-1385
50. N.P.Judd, A.E.Winkler, O.Murillo-Sauca, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012;72:365–374. doi:10.1158/0008-5472.CAN-11-1831
51. G.Sette, V.Salvati, L.Memeo, et al. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One. 2012;7:e46891. doi:10.1371/journal.pone.0046891
52. G.Kim, A.E.McKee, Y.M.Ning, et al. FDA approval summary:vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014;20:4994–5000. doi:10.1158/1078-0432.CCR-13-3045
53. T.Bowman, M.A.Broome, D.Sinibaldi, et al. STAT3–mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 2001;98:7319–7324. doi:10.1073/pnas.131568898
54. H.Yu, H.Lee, A.Herrmann, et al. Revisiting STAT3 signalling in cancer:new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–746. doi:10.1038/nrc3818
55. Y.Li, H.A.Rogoff, S.Keates, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112:1839–1844. doi:10.1073/pnas.1424171112• It demonstrates that the STAT3 inhibitor BBI608 can inhibit stemness gene expression.
56. M.R.Senger, C.A.Fraga, R.F.Dantas, et al. Filtering promiscuous compounds in early drug discovery:is it a good idea? Drug Discov Today. 2016;21:868–872. doi:10.1016/j.drudis.2016.02.004
57. I.V.Santaliz-Ruiz, E.Luis, X.Xie, et al. Emerging role of Nanog in tumorigenesis and cancer stem cells. Int J Cancer. 2014;135:2741–2748. doi:10.1002/ijc.28690
58. Y.Lu, H.Zhu, H.Shan, et al. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett. 2013;340:113–123. doi:10.1016/j.canlet.2013.06.021
59. H.A.Hirsch, D.Iliopoulos, P.N.Tsichlis, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–7511. doi:10.1158/0008-5472.CAN-08-3660
60. D.B.Shackelford, R.J.Shaw. The LKB1-AMPK pathway:metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–575. doi:10.1038/nrc2676
61. A.Janzer, N.J.German, K.N.Gonzalez-Herrera, et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A. 2014;111:10574–10579. doi:10.1073/pnas.1409844111
62. S.Cufí, A.Vazquez-Martin, C.Oliveras-Ferraros, et al. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT):from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010;9:4461–4468. doi:10.4161/cc.9.22.14048
63. L.Li, R.Han, H.Xiao, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014;20:2714–2726. doi:10.1158/1078-0432.CCR-13-3045
64. M.Kahn. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513–532. doi:10.1038/nrd4233
65. K.-Z.Zhang, Q.-B.Zhang, Q.-B.Zhang, et al. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol. 2014;7:28. doi:10.1186/1756-8722-7-28
66. M.De Menna, V.D’Amato, A.Ferraro, et al. Wnt4 inhibits cell motility induced by oncogenic Ras. Oncogene. 2013;32:4110–4119. doi:10.1038/onc.2012.419
67. J.N.Anastas, R.T.Moon. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
68. C.J.Eaves, R.K.Humphries. Acute myeloid leukemia and the Wnt pathway. N Engl J Med. 2010;362:2326–2327. doi:10.1056/NEJMcibr1003522
69. J.Monteiro, C.Gaspar, W.Richer, et al. Cancer stemness in Wnt-driven mammary tumorigenesis. Carcinogenesis. 2014;35:2–13. doi:10.1093/carcin/bgu107
70. F.de Sousa e Melo, L.Vermeulen. Wnt signaling in cancer stem cell biology. Cancers. 2016;8.pii:E60. doi:10.3390/cancers8070060
71. B.D.White, A.J.Chien, D.W.Dawson. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142:219–232. doi:10.1053/j.gastro.2011.12.001
72. J.K.Yoon, J.S.Lee. Cellular signaling and biological functions of R-spondins. Cell Sign. 2012;24:369–377. doi:10.1016/j.cellsig.2011.09.023
73. E.E.Storm, S.Durinck, F.de Sousa e Melo, et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature. 2016;529:97–100. doi:10.1038/nature16466
74. A.Gurney, F.Axelrod, C.J.Bond, et al. Wnt pathway inhibition via the targeting of frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012;109:11717–11722. doi:10.1073/pnas.1120068109• It shows that OMP-18R5, an antibody targeting Frizzled 7, inhibits the growth of a range of tumor types and reduces tumor-initiating cell frequency.
75. P.N.Le, J.D.McDermott, A.Jimeno. Targeting the Wnt pathway in human cancers:therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther. 2015;146:1–11. doi:10.1016/j.pharmthera.2014.08.005
76. G.-B.Jang, I.-S.Hong, R.-J.Kim, et al. Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res. 2015;75:1691–1702. doi:10.1158/0008-5472.CAN-14-3569
77. K.J.Leong, K.Niessen, I.Kulic, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through slug-induced repression of E-cadherin. J Exp Med. 2007;204:2935–2948. doi:10.1084/jem.20071082
78. E.R.Andersson, U.Lendahl. Therapeutic modulation of Notch signalling – are we there yet? Nat Rev Drug Discov. 2014;13:357–378. doi:10.1038/nrd4252
79. B.Cohen, M.Shimizu, J.Izrailit, et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat. 2010;123:113–124. doi:10.1007/s10549-009-0621-9
80. J.Domingo-Domenech, S.J.Vidal, V.Rodriguez-Bravo, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22:373–388. doi:10.1016/j.ccr.2012.07.016
81. C.Huynh, L.Poliseno, M.F.Segura, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One. 2011;6:e25264. doi:10.1371/journal.pone.0025264
82. D.C.Smith, P.D.Eisenberg, G.Manikhas, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014;20:6295–6303. doi:10.1158/1078-0432.CCR-14-1373
83. W.C.Yen, M.M.Fischer, F.Axelrod, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015;21:2084–2095. doi:10.1158/1078-0432.CCR-14-2808
84. I.Diaz-Padilla, M.K.Wilson, B.A.Clarke, et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer:a study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015;137:216–222. doi:10.1016/j.ygyno.2015.03.005
85. Teglund and Toftgård. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805:181–208.
86. D.Yue, H.Li, J.Che, et al. Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res. 2014;33:34. doi:10.1186/1756-9966-33-34
87. N.S.Chari, T.J.McDonnell. The sonic hedgehog signaling network in development and neoplasia. Adv Anat Pathol. 2007;14:344–352. doi:10.1097/PAP.0b013e3180ca8a1d
88. C.D’Amato, R.Rosa, R.Marciano, et al. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014;111:1168–1179. doi:10.1038/bjc.2014.421
89. J.Taipale, J.K.Chen, M.K.Cooper, et al. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature. 2000;406:1005–1009. doi:10.1038/35020557
90. A.Sekulic, M.R.Migden, A.E.Oro, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–2179. doi:10.1056/NEJMoa1113713
91. M.R.Migden, A.Guminski, R.Gutzmer, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT):a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–728. doi:10.1016/S1470-2045(15)70100-2
92. B.N.Singh, J.Fu, R.K.Srivastava, et al. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics:molecular mechanisms. PLoS One. 2011;6:e27306. doi:10.1371/journal.pone.0027306• It suggests that vismodegib can be used for the management of pancreatic cancer by targeting pancreatic CSCs.
93. E.J.Kim, V.Sahai, E.V.Abel, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014;20:5937–5945. doi:10.1158/1078-0432.CCR-13-3045
94. J.F.Santibañez, M.Quintanilla, C.Bernabeu. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci. 2011;121:233–251. doi:10.1042/CS20110086
95. D.X.Nguyen, P.D.Bos, J.Massagué. Metastasis:from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–284. doi:10.1038/nrc2622
96. H.Ohnuki, K.Jiang, D.Wang, et al. Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression. Cancer Res. 2014;74:2038–2049. doi:10.1158/0008-5472.CAN-13-3514
97. J.C.Morris, A.R.Tan, T.E.Olencki, et al. Phase I study of GC1008 (fresolimumab):a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9:e90353.
98. S.Y.Park, M.J.Kim, S.A.Park, et al. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget. 2015;6:37526–37543.
99. N.E.Bhola, J.M.Balko, T.C.Dugger, et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123:1348–1358. doi:10.1172/JCI65416• It demonstrates that TGF-β pathway inhibitors prevent the development of drug-resistant CSCs in triple-negative breast cancer.
100. M.Shiota, A.Zardan, A.Takeuchi, et al. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res. 2012;72:5261–5272. doi:10.1158/0008-5472.CAN-12-0254
101. S.Zhang, B.Cui, H.Lai, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem- cell therapy. Proc Natl Acad Sci U S A. 2014;111:17266–17271. doi:10.1073/pnas.1419599111
102. B.Cui, S.Zhang, L.Chen, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013;73:3649–3660.
103. Y.Hirohashi, T.Torigoe, T.Tsukahara, et al. Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci. 2016;107:12–17.
104. N.H.Segal, D.W.Parsons, K.S.Peggs, et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008;68:889–892. doi:10.1158/0008-5472.CAN-07-3095
105. K.Engelmann, H.Shen, O.J.Finn. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008;68:2419–2426.
106. C.Gedye, J.Quirk, J.Browning, et al. Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother. 2009;58:1635–1646. doi:10.1007/s00262-009-0672-0
107. A.M.Vlad, J.C.Kettel, N.M.Alajez, et al. MUC1 immunobiology:from discovery to clinical applications. Adv Immunol. 2004;82:249–293. doi:10.1016/S0065-2776(04)82006-6
108. M.Barve, J.Bender, N.Senzer, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008;26:4418–4425. doi:10.1200/JCO.2008.16.6462
109. J.Vansteenkiste, M.Zielinski, A.Linder, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;25:7554.
110. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239
111. F.S.Hodi, S.J.O’Day, D.F.McDermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. doi:10.1056/NEJMoa1011205• A phase III clinical trial demonstrating the effect of the anti-CTLA4 mAb ipilimumab in patients with metastatic melanoma.
112. K.Adachi, K.Tamada. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945–950. doi:10.1111/cas.12695
113. S.L.Topalian, M.Sznol, D.F.McDermott, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030. doi:10.1200/JCO.2013.54.6911• A dose-escalation trial showing the effects of the anti-PD1 mAb nivolumab in patients with advanced melanoma.
114. R.E.Sanborn, W.H.Sharfman, N.H.Segal, et al. A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. J Clin Oncol. 2013;31:abstr TPS3110. doi:10.1200/JCO.2013.49.0219
115. T.Z.Iversen, L.Engell-Noerregaard, E.Ellebaek, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res. 2014;20:221–232. doi:10.1158/1078-0432.CCR-13-1560
116. J.Nemunaitis, R.O.Dillman, P.O.Schwarzenberger, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24:4721–4730. doi:10.1200/JCO.2005.05.5335• A phase II clinical trial demonstrating the effects of a TGF-β2 antisense gene-modified allogeneic tumor cell vaccine in non–small-cell lung cancer.
117. P.W.Kantoff, C.S.Higano, N.D.Shore, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi:10.1056/NEJMoa1001294
118. M.S.Lawrence, P.Stojanov, P.Polak, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218. doi:10.1038/nature12213
119. N.Krawczyk, F.Meier-Stiegen, M.Banys, et al. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int. 2014;2014:415721. doi:10.1155/2014/415721